Across TCGA pan-cancer cohorts, LINC01600 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LINC01600 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LINC01600 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC01600 expression acts as an unfavorable survival marker.
HNSC, GBM, and UCEC are the cancer types where LINC01600 Mutation most reproducibly stratifies survival.